This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Non-Energy S&P 500 Stocks With Enough Energy to Boost Returns
by Kinjel Shah
Though energy companies have been among the best-performing stocks in the S&P 500 index, here we discuss some top-performing non-energy S&P 500 stocks like MRK, VRTX and MCK.
The Zacks Analyst Blog Highlights Merck, Bristol-Myers Squibb and Deere
by Zacks Equity Research
Merck, Bristol-Myers Squibb and Deere are included in this Analyst Blog.
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $108.78, moving -1.87% from the previous trading session.
Humana (HUM) Rises 23% in Past 6 Months: More Room to Run?
by Zacks Equity Research
Humana (HUM) is well-poised for growth on improving revenues, numerous contract wins and adequate cash-generating abilities.
Early Q4 Earnings Results and Analyst Reports for Merck, Bristol-Myers & Deere
by Sheraz Mian
Today's Research Daily features update on the Q4 earnings season and new research reports on Merck (MRK), Bristol-Myers (BMY) and Deere (DE).
Merck (MRK) Is Up 2.36% in One Week: What You Should Know
by Zacks Equity Research
Does Merck (MRK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Novartis' (NVS) PNH Candidate Achieves Study Objectives
by Zacks Equity Research
Novartis' (NVS) phase III study APPOINT-PNH evaluating investigational oral monotherapy iptacopan in complement-inhibitor-naive (including anti-C5 therapies) adults with PNH meets its primary endpoint.
Mirati (MRTX) Down After 1st-Line Lung Cancer Data on Adagrasib
by Zacks Equity Research
Mirati Therapeutics' (MRTX) preliminary data from the first-line NSCLC study showed that adagrasib plus Merck's Keytruda achieved an objective response rate of 49%.
4 Defensive Stocks to Prepare Your Portfolio for a Recession
by Anirudha Bhagat
Amid the rising possibility of a recession, defensive stocks with solid prospects will cushion investors from market jitters while their robust fundamentals ensure higher returns. ADM, HSY, UNH and MRK are some such stocks.
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adicet Bio, Inc. (ACET) and Merck (MRK) have performed compared to their sector so far this year.
Pfizer (PFE) Seeks FDA Nod for Bivalent COVID Jab in Infants
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech seek label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in young children under five years.
GSK's Myelofibrosis Candidate MAA Gets Accepted in Europe
by Zacks Equity Research
GSK's new drug application (NDA) for momelotinib is under standard FDA review, with a decision expected on Jun 16, 2023.
The Zacks Analyst Blog Highlights Caterpillar, Merck, UnitedHealth Group and Walmart
by Zacks Equity Research
Caterpillar, Merck, UnitedHealth Group and Walmart are included in this Analyst Blog.
Should Investors Consider These 3 Low-Beta Stocks?
by Derek Lewis
During times of heightened volatility, adding low-beta stocks can help blend in an extra layer of portfolio defense.
Top 4 Blue-Chip Stocks to Enhance Your Portfolio in December
by Nalak Das
We have narrowed our search to four Dow stocks. These are: CAT, WMT, MRK, UNH.
3 Reasons Growth Investors Will Love Merck (MRK)
by Zacks Equity Research
Merck (MRK) could produce exceptional returns because of its solid growth attributes.
Why Is Lilly (LLY) Up 4.5% Since Last Earnings Report?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
3 Stocks to Watch That Recently Announced Dividend Hikes
by Ritujay Ghosh
Merck & Co., Inc. (MRK), McCormick & Company, Incorporated (MKC) and Tsakos Energy Navigation Limited (TNP) recently hiked dividends.
AstraZeneca (AZN) Boosts Cell Therapies With Neogene Deal
by Zacks Equity Research
The acquisition of Neogene is set to give AstraZeneca (AZN) access to the latter's next-generation T-cell receptor therapies.
Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Should Invesco Dow Jones Industrial Average Dividend ETF (DJD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DJD
Factors That Make Elevance Health (ELV) a Lucrative Bet Now
by Zacks Equity Research
Elevance Health (ELV) continues to benefit from sustained top-line growth, higher membership in Government business and a sturdy financial position.
Should Value Investors Buy Innoviva (INVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Merck & Co., Inc. (MRK) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Merck (MRK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.